1. Home
  2. AKBA vs NRC Comparison

AKBA vs NRC Comparison

Compare AKBA & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Logo National Research Corporation (Delaware)

NRC

National Research Corporation (Delaware)

HOLD

Current Price

$18.08

Market Cap

390.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
NRC
Founded
2007
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.0M
390.8M
IPO Year
2014
1997

Fundamental Metrics

Financial Performance
Metric
AKBA
NRC
Price
$1.43
$18.08
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$5.25
N/A
AVG Volume (30 Days)
2.2M
62.6K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
3.63%
EPS Growth
93.94
4707.69
EPS
N/A
50.00
Revenue
N/A
$119,686,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.35
Revenue Growth
N/A
1.81
52 Week Low
$1.14
$9.76
52 Week High
$4.08
$22.79

Technical Indicators

Market Signals
Indicator
AKBA
NRC
Relative Strength Index (RSI) 51.31 61.60
Support Level $1.30 $17.85
Resistance Level $1.55 $18.18
Average True Range (ATR) 0.08 0.74
MACD 0.00 0.02
Stochastic Oscillator 42.37 82.48

Price Performance

Historical Comparison
AKBA
NRC

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About NRC National Research Corporation (Delaware)

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.

Share on Social Networks: